



STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

VISMODEGIB

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
VISMODEGIB	ERIVEDGE	38455		GPI-10 (2137007000)	

GUIDELINES FOR USE

1. Does the patient have a diagnosis of metastatic basal cell carcinoma **AND** meet the following criterion?

- The patient is 18 years of age or older

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**
If no, continue to #2.

2. Does the patient have a diagnosis of locally advanced basal cell carcinoma and meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- The patient's cancer has recurred following surgery or the patient is not a candidate for surgery or radiation

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #1 per day.**
If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **VISMODEGIB (Erivedge)** requires the following rule(s) be met for approval:

- A. You have metastatic basal cell carcinoma or locally advanced basal cell carcinoma (type of skin cancer that has spread in the body or is advanced but has not spread)
- B. You are 18 years of age or older
- C. **If you have locally advanced basal cell carcinoma, approval also requires:**
 - 1. Your cancer has returned after surgery OR you are not a candidate for surgery or radiation

Your doctor told us **[INSERT PT SPECIFIC INFO PROVIDED]**. We do not have information showing you **[INSERT UNMET CRITERIA]**. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

VISMODEGIB

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Erivedge.

REFERENCES

- Erivedge [Prescribing Information]. South San Francisco, CA: Genentech, Inc. , July 2020.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/22

Created: 02/12

Client Approval: 12/21

P&T Approval: 01/22